The collaboration will involve Evotec's Panomics platform, which integrates the analysis of genomic, transcriptomic, and proteomic data.
The partnership includes biopharmaceutical, life science, and non-profit organizations, as well as several US government agencies.
The companion diagnostic will leverage ArcherDx's Anchored Multiplex PCR technology, Illumina's MiSdqDx sequencer, and Archer Analysis bioinformatics software.
The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.
The RealTime PCR instrument identifies AML patients with IDH2 mutations who can be treated with Celgene's Idhifa.
The deal gives Celgene access to ImiDomics' database of genomic markers derived from biological samples for immune-mediated inflammatory diseases.
Most recently, Celgene has licensed the GNS platform for internal use and made an undisclosed equity investment in the company.
The partners aim to create a broad collection of high-quality genomic and clinical data from multiple myeloma patients to improve disease diagnosis, prognosis, and treatment.
Tempus will sequence and analyze pancreatic and melanoma cancer data from Penn patients to identify patterns associated with a positive response to treatment.
The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
In Science this week: in vitro generation of human reproductive cells, and more.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.